| Autor: |
Paul A. Monach, Roscoe L. Warner, Robert Lew, Gunnar Tómasson, Ulrich Specks, John H. Stone, Fernando C. Fervenza, Gary S. Hoffman, Cees G. M. Kallenberg, Carol A. Langford, Philip Seo, E. William St. Clair, Robert Spiera, Kent J. Johnson, Peter A. Merkel |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
ACR Open Rheumatology, Vol 4, Iss 2, Pp 168-176 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2578-5745 |
| DOI: |
10.1002/acr2.11366 |
| Popis: |
Objective Improved biomarkers of current disease activity and prediction of relapse are needed in antineutrophil cytoplasmic antibody–associated vasculitis (AAV). For clinical relevance, biomarkers must perform well longitudinally in patients on treatment and in patients with nonsevere flares. Methods Twenty‐two proteins were measured in 347 serum samples from 74 patients with AAV enrolled in a clinical trial. Samples were collected at Month 6 after remission induction, then every 3 months until Month 18, or at the time of flare. Associations of protein concentrations with concurrent disease activity and with future flare were analyzed using mixed‐effects models, Cox proportional hazards models, and conditional logistic regression. Results Forty‐two patients had flares during the 12‐month follow‐up period, and 32 remained in remission. Twenty‐two patients had severe flares. Six experimental markers (CXCL13, IL‐6, IL‐8, IL‐15, IL‐18BP, and matrix metalloproteinase‐3 [MMP‐3]) and ESR were associated with disease activity using all three methods (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text